Authors


Nour Abdallah, MD

Latest:

Race-based adjustment of eGFR: Current opinions and impact on urologic oncology

“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.


Deborah M. Shlian, MD, MBA

Latest:

Despite overall gains, leadership and payment gaps remain for women in medicine

"The good news is that women have been entering medicine in increasing numbers for more than three decades. The not-so-good news is that women are still underrepresented and underutilized in positions of power," writes Deborah M. Shlian, MD, MBA.


Armine K. Smith, MD

Latest:

EP. 4B: Educating Patients on Their Treatment Options for LG UTUC

In this companion article, Armine K. Smith, MD, reflects on the role of kidney-sparing approaches for LG UTUC and emphasizes the importance of patient-provider communication when making treatment decisions.


Chris Mazzolini

Latest:

Expert insight on ransomware: Is your practice prepared?

Ransomware has never been a more serious threat for health care organizations, even small medical practices.


Richard David, MD, FACS

Latest:

Closing Thoughts on Urology Practice Management and Treatment of Advanced Prostate Cancer

Closing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.


Meredith E. Donahue, APRN-BC

Latest:

How APPs can be involved with genitourinary cancer care

A nurse practitioner discusses how she supports multiple providers in a large academic practice.


Edward M. Schaeffer, MD, PhD

Latest:

Moving transperineal prostate biopsy into the clinic

Learning curve for technique is short, but capital expenditures are required.


Russell Libby, MD

Latest:

Expert Opinion: We cannot continue to ignore the problem of physician mental distress

"We need health systems, state medical boards and physician employment settings to commit to prioritizing physician wellbeing and provide the reassurances and resources that encourage physicians in need to seek help," writes Russell Libby, MD.


Victoria L. Neikam, Esq

Latest:

Malpractice Consult: How likely are you to face a medical malpractice lawsuit?

"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.


Firas F. Abdollah, MD

Latest:

Future Directions for Imaging and Biopsy in Prostate Cancer

The panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.


Todd Shryock

Latest:

US Chamber of Commerce asks for delay on non-compete rule

The request comes amid growing concerns about the rule’s implications for businesses and employees nationwide.


Julie N. Graff, MD

Latest:

Novel dual agents for advanced prostate cancer

A recap of presentations from AUA 2021 highlighting next steps using novel therapies as combination approaches to treat advanced prostate cancer.


Yale School of Medicine

Latest:

Yale Urology’s First Female Professor

"I hope this achievement serves as a positive example for young women...of what we can accomplish together!" says Leslie M. Rickey, MD, MPH.


Munir Ghesani, MD

Latest:

Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular Recurrence 

Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence. 


Katie Robinson

Latest:

MRI-based screening emerging as viable alternative to PSA testing

“MRI-based screening showed lower proportions of screening-positive cases, lower false positive rates, and higher PPVs [positive predictive values] than those of PSA-based screening,” noted Taek Min Kim, MD.


David Friede

Latest:

Is greater patient control of their personal health records a plus for physicians?

The Cures Act has teeth and consumers are becoming increasingly aware of their right to obtain their information.


Rina Lokaj

Latest:

DFS end point not reached with adjuvant nivolumab for locally advanced high-risk RCC

Patient subgroups that favored nivolumab vs placebo included patients with sarcomatoid features (HR, 0.42; 95% CI, 0.17-1.07), PD-L1 expression of 1% or greater (HR, 0.53; 95% CI, 0.22-1.29), and those with lower limit of normal hemoglobin at baseline (HR, 0.49; 95% CI, 0.25-1.49).


Moffitt Cancer Center

Latest:

Moffitt Study Suggests Improvements Needed for Patient-Reported Outcome Data in Genitourinary Cancer Clinical Studies

“Our data showed a considerable gap in reporting patient-reported outcomes and in the quality of design and conduct of patient-reported outcomes-related trial endpoints," said Jad Chahoud, MD, MPH.



Boris Gershman, MD

Latest:

Emulating target trials using observational evidence to inform clinical decision-making

"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.


Ron Southwick

Latest:

Ascension cyberattack’s impact felt in multiple states

Some Ascension hospitals continue to divert ambulances to other facilities for emergency treatment, but some of the system’s hospitals are accepting all patients.


Rizwan Nurani, MD

Latest:

Future Landscape of Prostate Cancer and Rectal Spacers

The expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.


Lucienne Marie Ide, MD, PhD

Latest:

Can remote patient monitoring help combat the staffing shortage?

"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.


Jason Hafron, MD

Latest:

Unmet Needs and Investigational Therapies in mCSPC

Dr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.


Scott Webster, MD

Latest:

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.


Evan R. Goldfischer, MD, MBA, FACS

Latest:

Chronic care management in the urologic oncology setting

CCM programs can engage multiple providers to care for patients while reducing in-person visits.


Jeremy D. Sherer, JD

Latest:

What you need to know about providing telehealth in 2023

Jeremy D. Sherer, JD, explains everything physicians need to know about using telemedicine in their practice in 2023.


Steffanie Robertus

Latest:

When it comes to urology teaching or learning opportunities, just say yes

"Despite the uncertain times, I am grateful to be a student in the field of medicine, where compassion is one of the traits that defines its practitioners," says PA student Steffanie Robertus.


Brian Richardson, MD

Latest:

Unmet Needs and Treatment Gaps in Prostate Cancer

The panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.


Melanie McGilloway, NP-C

Latest:

Comparing Leuprolide Formulations in Advanced Prostate Cancer

In the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.

© 2024 MJH Life Sciences

All rights reserved.